JP2018528261A5 - - Google Patents

Download PDF

Info

Publication number
JP2018528261A5
JP2018528261A5 JP2018525526A JP2018525526A JP2018528261A5 JP 2018528261 A5 JP2018528261 A5 JP 2018528261A5 JP 2018525526 A JP2018525526 A JP 2018525526A JP 2018525526 A JP2018525526 A JP 2018525526A JP 2018528261 A5 JP2018528261 A5 JP 2018528261A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
group
compound
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018525526A
Other languages
English (en)
Japanese (ja)
Other versions
JP6863981B2 (ja
JP2018528261A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/044767 external-priority patent/WO2017023774A1/en
Publication of JP2018528261A publication Critical patent/JP2018528261A/ja
Publication of JP2018528261A5 publication Critical patent/JP2018528261A5/ja
Application granted granted Critical
Publication of JP6863981B2 publication Critical patent/JP6863981B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018525526A 2015-07-31 2016-07-29 グルタミン類似体のプロドラッグ Active JP6863981B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562199566P 2015-07-31 2015-07-31
US62/199,566 2015-07-31
PCT/US2016/044767 WO2017023774A1 (en) 2015-07-31 2016-07-29 Prodrugs of glutamine analogs

Publications (3)

Publication Number Publication Date
JP2018528261A JP2018528261A (ja) 2018-09-27
JP2018528261A5 true JP2018528261A5 (https=) 2019-09-05
JP6863981B2 JP6863981B2 (ja) 2021-04-21

Family

ID=57943518

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018525526A Active JP6863981B2 (ja) 2015-07-31 2016-07-29 グルタミン類似体のプロドラッグ

Country Status (22)

Country Link
US (4) US10336778B2 (https=)
EP (1) EP3328827B1 (https=)
JP (1) JP6863981B2 (https=)
KR (1) KR102666477B1 (https=)
CN (2) CN108290827B (https=)
AU (1) AU2016302940B2 (https=)
CA (1) CA2994258C (https=)
DK (1) DK3328827T3 (https=)
EA (1) EA034571B1 (https=)
ES (1) ES2957583T3 (https=)
FI (1) FI3328827T3 (https=)
HR (1) HRP20231163T1 (https=)
HU (1) HUE063399T2 (https=)
IL (1) IL257219B (https=)
LT (1) LT3328827T (https=)
MX (1) MX384906B (https=)
PL (1) PL3328827T3 (https=)
PT (1) PT3328827T (https=)
RS (1) RS64597B1 (https=)
SI (1) SI3328827T1 (https=)
SM (1) SMT202300320T1 (https=)
WO (1) WO2017023774A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2994165A1 (en) 2015-07-31 2017-02-09 The Johns Hopkins University Methods for cancer and immunotherapy using glutamine analogues, including don
AU2016302940B2 (en) 2015-07-31 2021-02-04 The Johns Hopkins University Prodrugs of glutamine analogs
EP3328374A4 (en) * 2015-07-31 2019-03-13 The Johns Hopkins University GLUTAMINANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITES
US10842763B2 (en) 2015-07-31 2020-11-24 The Johns Hopkins University Methods for cancer and immunotherapy using prodrugs of glutamine analogs
CA3052283A1 (en) 2017-02-01 2018-08-09 The Johns Hopkins University Prodrugs of glutamine analogs
CN111566083A (zh) * 2017-10-06 2020-08-21 约翰·霍普金斯大学 新的谷氨酰胺拮抗剂及其用途
SG11202107317WA (en) * 2019-01-18 2021-08-30 Dracen Pharmaceuticals Inc Combinaton therapy with a don prodrug and an immune checkpoint inhibitor
JP2022519574A (ja) * 2019-02-11 2022-03-24 ドラセン ファーマシューティカルズ インコーポレイテッド Ｌ－グルタミン酸からｄｏｎプロドラッグを調製する方法
US11760723B2 (en) 2019-02-11 2023-09-19 Dracen Pharmaceuticals, Inc. Method of preparing a DON prodrug from L-pyroglutamic acid
CA3153424A1 (en) * 2019-10-03 2021-04-08 Dracen Pharmaceuticals, Inc. Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereof
CN110763792A (zh) * 2019-10-24 2020-02-07 湖北省宏源药业科技股份有限公司 一种鸟嘌呤有关物质检测方法
WO2021239049A1 (en) * 2020-05-27 2021-12-02 Jacobio Pharmaceuticals Co., Ltd. Novel glutamine analogs
WO2022022612A1 (en) * 2020-07-29 2022-02-03 Jacobio Pharmaceuticals Co., Ltd. Novel glutamine analogs
JP7846686B2 (ja) * 2020-10-02 2026-04-15 ドラセン ファーマシューティカルズ インコーポレイテッド 皮下投与のための（ｓ）－イソプロピル２－（（ｓ）－２－アセトアミド－３－（１ｈ－インドール－３－イル）プロパンアミド）－６－ジアゾ－５－オキソヘキサノエートを含む凍結乾燥組成物およびその使用
WO2022078462A1 (en) * 2020-10-15 2022-04-21 Jacobio Pharmaceuticals Co., Ltd. Novel glutamine analogs
EP4229029B1 (en) * 2020-10-15 2026-02-25 Jacobio Pharmaceuticals Co., Ltd. Novel glutamine analogs
CN114621120B (zh) * 2020-12-10 2023-11-03 深圳先进技术研究院 一种don前药分子、前药激活化合物和前药激活体系
US20240246902A1 (en) * 2021-04-29 2024-07-25 The Johns Hopkins University Prodrugs of 6-diazo-5-oxo-l-norleucine
WO2022261117A1 (en) * 2021-06-07 2022-12-15 Dracen Pharmaceuticals, Inc. Combination therapy with a don prodrug and a tigit inhibitor
CN113461563B (zh) * 2021-07-27 2022-05-10 中国药科大学 Nqo1激活型6-重氮基-5-氧代-l-正亮氨酸前药及其制备方法和应用
CN114306620A (zh) * 2021-12-07 2022-04-12 深圳先进技术研究院 基于代谢检查点的人血清白蛋白纳米药物及其制备方法和应用
JP2025078888A (ja) * 2022-01-28 2025-05-21 国立大学法人富山大学 グルタミナーゼ阻害剤
CN114917230B (zh) * 2022-03-09 2023-03-24 山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院) Cb-839在制备抑制角膜新生血管生成的药物中的应用
TW202406539A (zh) * 2022-04-21 2024-02-16 大陸商北京加科思新藥研發有限公司 藥物組合及其用途
TW202404938A (zh) * 2022-04-21 2024-02-01 大陸商北京加科思新藥研發有限公司 麩醯胺酸拮抗劑的多晶型及其用途
CN114805138B (zh) * 2022-05-12 2023-10-10 中国科学院长春应用化学研究所 6-重氮-5-氧代-l-正亮氨酸的前药、其制备方法及应用
WO2024094526A1 (en) 2022-11-02 2024-05-10 Ecole Polytechnique Federale De Lausanne (Epfl) 6-diazo-5-oxo-l-norleucine prodrugs

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US121179A (en) * 1871-11-21 Improvement in brick-kilns
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4503044A (en) * 1983-04-25 1985-03-05 American Cyanamid Company Antibiotic LL-D05139 β
US4568646A (en) * 1983-04-25 1986-02-04 American Cyanamid Company Preparation of antibiotic LL-D05139β from cultures of Glycomyces harbinensis, gen. nov., sp. nov.
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
SK285353B6 (sk) * 1996-04-12 2006-11-03 G. D. Searle & Co. Substituované benzénsulfónamidy ako proliečivá COX-2 inhibítorov, farmaceutická kompozícia a spôsobich prípravy a použitia
WO2001041707A2 (en) 1999-12-08 2001-06-14 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
US7419670B2 (en) 2000-09-29 2008-09-02 Viron Therapeutics, Inc. Method of treating arthritis with SERP-1 and an immunosuppressant
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7605150B2 (en) 2002-05-14 2009-10-20 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
AU2003294221A1 (en) * 2002-09-13 2004-04-19 Kenneth E. Miller Method of alleviating pain via inhibition of neurotransmitter synthesis
GB0314262D0 (en) * 2003-06-19 2003-07-23 Univ Nottingham Trent Novel compounds and methods of using the same
KR20110097942A (ko) 2003-08-20 2011-08-31 제노포트 인코포레이티드 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
BRPI0506939A (pt) 2004-01-19 2007-06-12 Novartis Ag derivados de indolilmaleimida como inibidores de pkc
JP2007532506A (ja) 2004-04-08 2007-11-15 ノバルティス アクチエンゲゼルシャフト 自己免疫疾患および拒絶反応の処置のためのタンパク質キナーゼｃ阻害剤
US20060276438A1 (en) 2004-10-04 2006-12-07 Natarajan Sethuraman Prevention and treatment of influenza with glutamine antagonist agents
EP1874342B1 (en) 2005-04-26 2018-06-06 Eisai R&D Management Co., Ltd. Compositions and methods for cancer immunotherapy
BRPI0708615A2 (pt) 2006-03-07 2011-06-07 Array Biopharma Inc compostos de pirazol heterobicìclicos e métodos de uso
US8465736B2 (en) 2006-05-10 2013-06-18 New Medical Enzymes Ag Glutadon
WO2008033572A1 (en) 2006-09-15 2008-03-20 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US20080107623A1 (en) 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US20080160024A1 (en) 2006-12-07 2008-07-03 Board Of Trustees Of The University Of Arkansas Inhibition of cancer metastasis
WO2009029729A1 (en) 2007-08-31 2009-03-05 Genelabs Technologies, Inc. Amino tricyclic-nucleoside compounds, compositions, and methods of use
US8580312B2 (en) 2010-02-17 2013-11-12 National University Corporation Kobe University Radiation therapy agent
AU2011270701B2 (en) 2010-06-24 2015-05-14 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
JP6130307B2 (ja) 2011-03-17 2017-05-17 ザ ユニバーシティ オブ バーミンガム 再指向性免疫療法
KR101900478B1 (ko) 2011-08-04 2018-09-20 한올바이오파마주식회사 암의 재발 또는 전이의 억제용 약제학적 조성물
US20160008380A1 (en) * 2013-03-06 2016-01-14 The Johns Hopkins University Targeting glutamine metabolism in brain tumors
US20160022708A1 (en) 2013-03-14 2016-01-28 St. Jude Children's Research Hospital Methods and compositions for the treatment of glutamine-addicted cancers
WO2015035112A1 (en) 2013-09-05 2015-03-12 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation
KR20160093012A (ko) 2013-11-05 2016-08-05 코그네이트 바이오서비시즈, 인코포레이티드 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물
JP2017500313A (ja) * 2013-12-09 2017-01-05 ブレット バイオテクノロジー， インコーポレーテッドＢｕｌｌｅｔ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． 特異的ウイルス様粒子−ＣｐＧオリゴヌクレオチドワクチンおよびその使用
CA2934700A1 (en) 2014-01-06 2015-07-09 Rhizen Pharmaceuticals Sa Glutaminase inhibitors
EP3116872A4 (en) 2014-03-14 2017-08-30 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
KR20170012562A (ko) 2014-06-13 2017-02-02 칼리테라 바이오사이언시즈 인코포레이티드 글루타미나제 억제제를 사용하는 병용 요법
US10864180B2 (en) 2015-04-23 2020-12-15 The Johns Hopkins University Combination of immunotherapy with local chemotherapy for the treatment of malignancies
US10842763B2 (en) 2015-07-31 2020-11-24 The Johns Hopkins University Methods for cancer and immunotherapy using prodrugs of glutamine analogs
EP3328374A4 (en) 2015-07-31 2019-03-13 The Johns Hopkins University GLUTAMINANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITES
CA2994165A1 (en) 2015-07-31 2017-02-09 The Johns Hopkins University Methods for cancer and immunotherapy using glutamine analogues, including don
AU2016302940B2 (en) 2015-07-31 2021-02-04 The Johns Hopkins University Prodrugs of glutamine analogs

Similar Documents

Publication Publication Date Title
JP2018528261A5 (https=)
JP2021513534A5 (https=)
JP2011219498A5 (https=)
IL276322B2 (en) Lipid-like nanocomplexes and uses thereof
JP2020169171A5 (https=)
JP2021532162A5 (https=)
JP2014503574A5 (https=)
JP2015522650A5 (https=)
JP2019512478A5 (https=)
JP2017509586A5 (https=)
RU2015118647A (ru) Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr
JP2014503567A5 (https=)
JP2014532716A5 (https=)
JP2019524883A5 (https=)
JP2016053042A5 (https=)
JP2010527913A5 (https=)
JP2006505543A5 (https=)
JP2008510828A5 (https=)
JP2008509166A5 (https=)
JP2016519072A5 (https=)
RU2018127728A (ru) Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич
JP2019510810A5 (https=)
JP2010511721A5 (https=)
JP2019500387A5 (https=)
JP2017511321A5 (https=)